JP2004537252A5 - - Google Patents

Download PDF

Info

Publication number
JP2004537252A5
JP2004537252A5 JP2001537498A JP2001537498A JP2004537252A5 JP 2004537252 A5 JP2004537252 A5 JP 2004537252A5 JP 2001537498 A JP2001537498 A JP 2001537498A JP 2001537498 A JP2001537498 A JP 2001537498A JP 2004537252 A5 JP2004537252 A5 JP 2004537252A5
Authority
JP
Japan
Prior art keywords
polypeptide
cell
isolated
cells
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001537498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537252A (ja
Filing date
Publication date
Priority claimed from US09/439,313 external-priority patent/US6329505B1/en
Application filed filed Critical
Priority claimed from PCT/US2000/030904 external-priority patent/WO2001034802A2/en
Publication of JP2004537252A publication Critical patent/JP2004537252A/ja
Publication of JP2004537252A5 publication Critical patent/JP2004537252A5/ja
Pending legal-status Critical Current

Links

Images

JP2001537498A 1999-11-12 2000-11-09 前立腺癌の治療及び診断のための組成物及び方法 Pending JP2004537252A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/439,313 US6329505B1 (en) 1997-02-25 1999-11-12 Compositions and methods for therapy and diagnosis of prostate cancer
US44368699A 1999-11-18 1999-11-18
PCT/US2000/030904 WO2001034802A2 (en) 1999-11-12 2000-11-09 Compositions and methods for the therapy and diagnosis of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009017430A Division JP2009142284A (ja) 1999-11-12 2009-01-29 前立腺癌の治療および診断のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2004537252A JP2004537252A (ja) 2004-12-16
JP2004537252A5 true JP2004537252A5 (OSRAM) 2008-05-22

Family

ID=27032000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001537498A Pending JP2004537252A (ja) 1999-11-12 2000-11-09 前立腺癌の治療及び診断のための組成物及び方法

Country Status (5)

Country Link
EP (1) EP1230364A2 (OSRAM)
JP (1) JP2004537252A (OSRAM)
AU (1) AU1656501A (OSRAM)
CA (1) CA2391369A1 (OSRAM)
WO (1) WO2001034802A2 (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6657056B2 (en) 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
ES2324503T3 (es) 1997-04-10 2009-08-07 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, genes pca3 y metodos de uso.
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DK1086223T3 (da) 1998-06-01 2009-11-30 Agensys Inc Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
PT1222266E (pt) 1999-09-29 2006-07-31 Diagnocure Inc Arn mensageiro de pca3 em tecidos benignos e malignos da prostata
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
PT1517913E (pt) * 1999-10-07 2007-05-31 Corixa Corp Sequência codificante de mycobacterium turberculosis para expressão de proteínas heterólogas.
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
EP1261708A2 (en) * 2000-01-14 2002-12-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1311673A2 (en) * 2000-03-27 2003-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20020009455A1 (en) * 2000-04-27 2002-01-24 Ted Lau DNA encoding a novel PROST 03 polypeptide
AU6867801A (en) 2000-06-20 2002-01-02 Corixa Corp Fusion proteins of mycobacterium tuberculosis
CA2422642A1 (en) * 2000-10-03 2002-04-11 Human Genome Sciences, Inc. Human prostate specific g-protein receptor hpraj70
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
CA2459318C (en) 2001-09-06 2017-09-26 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ATE359295T1 (de) * 2002-06-11 2007-05-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzungen
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
EP1636379A2 (en) 2003-06-26 2006-03-22 Exonhit Therapeutics S.A. Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
DK1742966T3 (da) 2004-04-22 2014-02-03 Agensys Inc Antistoffer og molekyler afledt deraf som binder til STEAP-1 proteiner
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
CA2667019C (en) 2006-10-27 2016-03-29 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
ES2955852T3 (es) 2017-04-03 2023-12-07 Hoffmann La Roche Anticuerpos de unión a STEAP-1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
KR19990087802A (ko) * 1996-03-15 1999-12-27 길리스 스티브 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법
CN1195851C (zh) * 1997-02-25 2005-04-06 科里克萨有限公司 用于前列腺癌免疫疗法的化合物及其用途
DE69831222T2 (de) * 1997-02-25 2006-07-13 Corixa Corp., Seattle Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
WO1998050567A1 (en) * 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
CA2331769A1 (en) * 1998-06-22 1999-12-29 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes
TW200728465A (en) * 1998-07-14 2007-08-01 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer

Similar Documents

Publication Publication Date Title
JP2004537252A5 (OSRAM)
Fallarino et al. Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo
AU749544B2 (en) Tumor antigen peptides originating in cyclophilin B
EP2626081B1 (en) Immunogenic control of tumours and tumour cells
JP2005504513A5 (OSRAM)
JP2002505843A5 (OSRAM)
ES2373055T3 (es) Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
CA2245702A1 (en) Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same
JP2021536435A (ja) 核酸とｃａｒ修飾免疫細胞とを含む治療薬およびその使用
CA2641565A1 (en) Nel-related proteins type 1 and 2, and polynucleotides encoding them
JP2020502262A5 (OSRAM)
JP2006515749A5 (OSRAM)
CN113785048B (zh) 用于扩增和分化在过继转移疗法中的t淋巴细胞和nk细胞的方法
JP2001516226A (ja) 腫瘍関連性の抗原に対する免疫応答を誘導するための組成物および方法
TW202146435A (zh) 含有病原性抗原及免疫刺激物之組合物
CA2262756A1 (en) A tumor necrosis factor related ligand
AU2013249522A1 (en) Multivalent breast cancer vaccine
CA2522994A1 (en) Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
AU2020256402A1 (en) Hla-g specific chimeric antigen receptor, nucleic acid, hla-g specific chimeric antigen receptor expression plasmid, hla-g specific chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer
Colluru et al. Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses
JP2002512800A5 (OSRAM)
CN115814091A (zh) Cd43抑制剂在制备抗结直肠肿瘤药物中的用途
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
JP2003529608A5 (OSRAM)
Nelson et al. Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products